ACETAZOLAMIDE SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Acetazolamide Sodium patents expire, and when can generic versions of Acetazolamide Sodium launch?
Acetazolamide Sodium is a drug marketed by Avet Lifesciences, Endo Operations, Hikma, Hospira, Mylan Asi, Xgen Pharms, and Zydus Pharms. and is included in seven NDAs.
The generic ingredient in ACETAZOLAMIDE SODIUM is acetazolamide sodium. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the acetazolamide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acetazolamide Sodium
A generic version of ACETAZOLAMIDE SODIUM was approved as acetazolamide sodium by HIKMA on February 28th, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACETAZOLAMIDE SODIUM?
- What are the global sales for ACETAZOLAMIDE SODIUM?
- What is Average Wholesale Price for ACETAZOLAMIDE SODIUM?
Summary for ACETAZOLAMIDE SODIUM
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 9 |
Clinical Trials: | 9 |
Patent Applications: | 143 |
DailyMed Link: | ACETAZOLAMIDE SODIUM at DailyMed |
Recent Clinical Trials for ACETAZOLAMIDE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
JDRF | Phase 1/Phase 2 |
University of California, San Diego | Phase 1/Phase 2 |
The Leona M. and Harry B. Helmsley Charitable Trust | Phase 1/Phase 2 |
Pharmacology for ACETAZOLAMIDE SODIUM
Drug Class | Carbonic Anhydrase Inhibitor |
Mechanism of Action | Carbonic Anhydrase Inhibitors |